Abstract
Heart failure is a major global healthcare concern. The condition is associated with high morbidity, high mortality and a reduced quality of life. The prognosis of heart failure is poor, with a 5-year survival rate close to 50%. Pharmacological treatment is a cornerstone of heart failure care, helping to improve outcomes and quality of life for people living with the condition. The sodium–glucose co-transporter-2 (SGLT2) inhibitors dapagliflozin and empagliflozin have been approved for patients who have heart failure with reduced ejection fraction, mildly reduced ejection fraction and preserved ejection fraction. This article discusses the evidence base, mechanism of action, clinical indications and practical considerations for the use of SGLT2 inhibitors in the treatment of heart failure.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
